Navigation Links
Genomma Lab Announces Its 2010 Earnings Guidance
Date:12/11/2009

MEXICO CITY, Dec. 11 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company") announces today its 2010 earnings guidance.

Genomma Lab expects net sales growth in the range of 42% to 45% for the full year of 2010, excluding possible acquisitions, and an EBITDA margin between 25.0% and 26.0%, from 2009 year-end results which we expect to be above our last issued guidance.

The Company's estimates are based on organic growth in base line products, the full year effect in sales of products launched or acquired during 2009, growth in international operations as well as product line extensions and new brands in existing and new categories.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model.

    Contact: Oscar Villalobos
    Tel:  +52 (55) 5081- 0000 ext. 4250
    E-mail: inversion@genommalab.com

    In New York: i-advize Corporate Communications, Inc.
    Tel: (212) 406-3695
    E-mail: genomma@i-advize.com

SOURCE Genomma Lab Internacional, S.A.B. de C.V.


'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Strategic Alliance Between Televisa and Genomma Lab
2. Genomma Lab Internacional Revises 2009 Earnings Guidance
3. Strategic Alliance Between Televisa and Genomma Lab
4. Genomma Lab International Announces Second Quarter 2009 Results
5. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. Announces Second Quarter 2009 Results Conference Call
6. Genomma Lab Internacional Acquires Brands Flor de Naranja Sanborns(MR), Teatrical and Henna Egipcia From Grupo Sanborns
7. Genomma Lab Internacional Announces First Quarter 2009 Results
8. Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales
9. Genomma Lab Internacional Announces Fourth Quarter and Full Year 2008 Results
10. Webcast Alert: Genomma Lab Announces Fourth Quarter 2008 Earnings Webcast
11. Genomma Lab Announces Updated Fourth Quarter 2008 Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
Breaking Medicine Technology: